{"name":"K36 Therapeutics, Inc.","slug":"k36-therapeutics-inc","ticker":"","exchange":"","domain":"k36.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijAJBVV95cUxNX2JYOEdkQTZyYngxUURIeDdRUGZVMnZNSy1yb0hvYzBubHBvX29nUnNFc3B0T2R6T2pta0IzTV9OTjVZVUt6Q1NVcXUta19kN082c1FDSENoMWZFVEFmNUZzN3lkbjlTNjQwZGtUYW91bzEwdFNoZHZyWkJiZlZPRm5zYkQwR2ozYWRSa3VfZ1R3ZG9RNzFTTGVyNWxZbmJtRVNubTY1OXQtY0o3Z0hIQ1I1QXVqQzFiOXVJY2IyWG50MkdzQjY1eHZvbGR4azJFRU1NVkx0Wl80dVpUTVZRbDVNZDZPNHZEekxtYklaY0lzOGg5amJhclh5YmNWSHdXc0lKbVBweXdGQWpN?oc=5","date":"2026-02-05","type":"trial","source":"prnewswire.com","summary":"K36 Therapeutics Completes Dosing of First Cohort in Phase 1 Clinical Trial of KTX-2001 in Prostate Cancer, Announces New CMO - prnewswire.com","headline":"K36 Therapeutics Completes Dosing of First Cohort in Phase 1 Clinical Trial of KTX-2001 in Prostate Cancer, Announces Ne","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-12-05","type":"trial","source":"prnewswire.com","summary":"K36 Therapeutics announces presentation of First-in-Human Clinical Data for Gintemetostat (KTX-1001) Demonstrating Target Engagement and Clinical Activity in Multiple Myeloma at ASH 2025 and the Appoi","headline":"K36 Therapeutics announces presentation of First-in-Human Clinical Data for Gintemetostat (KTX-1001) Demonstrating Targe","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiuwJBVV95cUxNN2RYa0ZlWURQTWhLYVloU29JX25rbERIYXNoRGlRcFFKUExmLTZ6WEdhZDNZNkE4UlFyMTVvc25NNXpCMndRMWV2N2NtdnpHT1ZUNEkzcThCQjk5ZkhUSWVZY1Z4T1VVUnJmWE1ualIxbC1UQ2xtbzBNeFpKRUt1S3Q2TkVIZjE5bXpUUi1ra0pfNWl6a1pyMG43bFV0VDdwYkJHT1c5SFVUQmlMVzIxaXMtRHJueTBrYTJORDZrbFF2YkxfX1ZNa3UwS2ZjaWVIa0g1M2ZQN3g2WWx0WUtYejNDWHF5LUpOOENBcFJXTE1CUklIb3FLay1UMnNkN1hJaTZ2V3FUN2Y5V3NHOF90WllVcDd4cmRRZTF0aGYxV0NCdURZUWhyQ0NhbTduY2hldVZXemtuemg1bUk?oc=5","date":"2025-09-18","type":"trial","source":"prnewswire.com","summary":"K36 Therapeutics to Present New Preclinical Data Supporting Ongoing Phase 1 Clinical Trial of KTX-1001 at the 22nd Annual International Myeloma Society Meeting - prnewswire.com","headline":"K36 Therapeutics to Present New Preclinical Data Supporting Ongoing Phase 1 Clinical Trial of KTX-1001 at the 22nd Annua","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxOYTF1NVdocmI4ZTg5ZlNsLVVOQmQ1MTJrS0VxWEh0aW9JUTR6OG01THJPSTF4MzlEOThaTVhRUzBYZ3lHd2g1ak9SbzhuTEw1dUVIQXdBV3VwX0JQcGhIYVRCT2xpQXNLN18tX0pxTHJ1Z1pQTHRwRVNybXlpM013YzFlRURnMUdNV0FVZXVTbkFWTXAtTnZPdzRhMERsRW1FODh5LXgtYW5YcHFNQTZDX3JYSzRYcERXbW9KcXhGckV4bDVGbUV1ZQ?oc=5","date":"2025-09-16","type":"pipeline","source":"prnewswire.com","summary":"K36 Therapeutics Provides Clinical Update on KTX-1001 in Multiple Myeloma - prnewswire.com","headline":"K36 Therapeutics Provides Clinical Update on KTX-1001 in Multiple Myeloma","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-08-08","type":"regulatory","source":"BioSpace","summary":"K36 Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for KTX-2001 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Announces Clinical Trial Collaboration","headline":"K36 Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for KTX-2001 in Metastatic Castrat","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2024-12-03","type":"regulatory","source":"prnewswire.com","summary":"K36 Therapeutics Announces Multiple Poster Presentations Highlighting the First Clinical Data for KTX-1001 and Other Developmental Compounds at the 66th American Society of Hematology (ASH) Annual Mee","headline":"K36 Therapeutics Announces Multiple Poster Presentations Highlighting the First Clinical Data for KTX-1001 and Other Dev","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTFB6OGFaQzM1TXpIOEJWVm5ReUVsLWM1c19EU2t0cUhZdFZfOGVrR3lxcGRMWEVHU25VYUdZelBGd0t1ZzhtdUk3TlNIWE4wdnhXa3ZYMmdndG0wdEhWUnVxRy14aEZWbnAyMmxVZQ?oc=5","date":"2024-08-02","type":"pipeline","source":"labiotech.eu","summary":"Six epigenetics companies making strides in 2024 - labiotech.eu","headline":"Six epigenetics companies making strides in 2024","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxNTlZHR1ZoNFJQVXNKUWtseEdPZ2pJckg0Z19mZVVGRkk5VVh0UzBzSmQxSjlENzZrcEhrRjNvV01yYktSYXNnS0otTzBkVkJvMGx4dVRqRnpNN0lIOURpMXZxVEFoeDRaME1FUHg3N0lEbDR4eldHekE4a3NKRHJEZ2RCaEJiSzE2am41b0VKTzhMUmtUdjhKUkZEVjc?oc=5","date":"2023-11-15","type":"pipeline","source":"Contract Pharma","summary":"K36 Therapeutics Names Benjamin Winograd Chief Medical Officer - Contract Pharma","headline":"K36 Therapeutics Names Benjamin Winograd Chief Medical Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_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?oc=5","date":"2023-06-28","type":"pipeline","source":"prnewswire.com","summary":"K36 Therapeutics Announces $70 Million Series B Financing to Fund Clinical Proof of Concept of KTX-1001, First-in-class Inhibitor of MMSET for Treatment of Multiple Myeloma Patients with Genetic Trans","headline":"K36 Therapeutics Announces $70 Million Series B Financing to Fund Clinical Proof of Concept of KTX-1001, First-in-class ","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2023-04-11","type":"trial","source":"prnewswire.com","summary":"K36 Therapeutics announces dosing of first patient in KTX-1001 Phase 1 Clinical Trial for relapsed or refractory multiple myeloma and addition of Mr. Michael Heffernan as Independent Board Director - ","headline":"K36 Therapeutics announces dosing of first patient in KTX-1001 Phase 1 Clinical Trial for relapsed or refractory multipl","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}